VCBeat Health Contact Us
Home Maiji Biotechnology Announces Positive Topline Results from Phase III Trial of Komeiqibaimab (MG-K10) in Prurigo Nodularis

Maiji Biotechnology Announces Positive Topline Results from Phase III Trial of Komeiqibaimab (MG-K10) in Prurigo Nodularis

May 30, 2026 10:30 CST Updated 14:02
CMS

Professional Drug Developer